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Summary
Purpose:  Vigabatrin-associated  visual  ﬁeld  loss  (VAVFL)  occurs  in  around  45%  of  exposed  people.
It is  generally  accepted  that,  once  established,  VAVFL  is  stable  and  does  not  progress  with
continued  VGB  use.  Most  studies  have,  however,  only  followed  people  for  short  periods.  We
assessed  the  evolution  of  VAVFL  over  a  ten-year  period  of  continued  VGB  use.
Methods:  From  a  group  of  201  vigabatrin-exposed  individuals  with  epilepsy,  fourteen  individuals
were identiﬁed  who  were  currently  taking  vigabatrin.  All  individuals  had  at  least  ten  years
exposure  to  vigabatrin.  Individuals  underwent  several  visual  ﬁeld  examinations  using  Goldmann
perimetry  between  Test  1  (ﬁrst  recorded  examination)  and  Test  2  (most  recent  examination).
All visual  ﬁeld  results  were  analysed  and  quantiﬁed  retrospectively  by  one  investigator.
Results:  174  visual  ﬁelds  from  the  fourteen  participants  were  available.  The  average  follow-up
period was  128  months.  The  prevalence  of  VAVFL  increased  from  64%  at  Test  1  to  93%  at  Test  2.
The visual  ﬁeld  size  was  signiﬁcantly  smaller  at  Test  2  compared  to  Test  1.  All  subjects  showed
a trend  for  decreasing  visual  ﬁeld  size  with  increasing  cumulative  vigabatrin  exposure,  when
all ﬁelds  for  an  individual  were  taken  into  account.  There  was  a  high  degree  of  variability  in
visual ﬁeld  size  between  successive  test  sessions.
Conclusions:  VAVFL  progresses  with  continued  vigabatrin  exposure  over  a  ten-year  period.  Pro-
gression may  be  slow  and  difﬁcu
ﬁeld size  between  successive  te
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Introduction
Exposure  to  the  antiepileptic  drug  vigabatrin  (VGB)  is  associ-
ated  with  the  development  of  visual  ﬁeld  loss  in  around  45%
of  people  (Maguire  et  al.,  2010).  It  is  generally  accepted
that,  once  established,  vigabatrin-associated  visual  ﬁeld
loss  (VAVFL)  is  stable  and  does  not  progress  with  contin-
ued  VGB  use  (Paul  et  al.,  2001).  Several  follow-up  studies
of  individuals  who  continue  VGB  have  shown  no  progres-
sion  of  VAVFL  over  time  (Lawden  et  al.,  1999;  Nousiainen
et  al.,  2001;  Paul  et  al.,  2001;  Graniewski-Wijnands  and
van  der  Torren,  2002;  Schmidt  et  al.,  2002;  Best  and
Acheson,  2005)  (Table  1).  In  addition,  increasing  cumu-
lative  VGB  exposure  (Kalviainen  et  al.,  1999;  Nousiainen
et  al.,  2001;  Newman  et  al.,  2002;  Nicolson  et  al.,  2002;
Kinirons  et  al.,  2006)  and  longer  duration  of  VGB  expo-
sure  (Nousiainen  et  al.,  2001;  Comaish  et  al.,  2002;  Kinirons
et  al.,  2006;  Newman  et  al.,  2002;  Vanhatalo  et  al.,
2002)  were  not  found  to  be  associated  with  increased
risk  of  VAVFL,  further  suggesting  that  VGB  retinotoxic-
ity  does  not  show  a  progressive  evolution  with  continued
use.
Conversely,  other  studies  have  reported  that  higher
cumulative  VGB  exposure  (Lawden  et  al.,  1999;  Manuchehri
et  al.,  2000;  Hardus  et  al.,  2001;  Malmgren  et  al.,  2001;
Frisen,  2004),  and  longer  duration  of  therapy  (Lawden  et  al.,
1999;  Hardus  et  al.,  2001;  Malmgren  et  al.,  2001;  Toggweiler
and  Wieser,  2001;  Schmitz  et  al.,  2002)  are  associated  with
increased  risk  of  VAVFL.  In  addition,  occasional  reports  have
arisen  of  progression  of  VAVFL  with  continued  VGB  use
(Lawden  et  al.,  1999;  Hardus  et  al.,  2000,  2003;  Clayton
et  al.,  2010)  (Table  1).
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Table  1  Summary  of  follow-up  studies  reporting  changes  in  the  v
Reference Number  of
participants
F
Clayton  et  al.  (2010)  1  1
Kinirons  et  al.  (2006)  41  
Hardus  et  al.  (2000) c 11  
Best  and  Acheson  (2005)  16  
Lawden  et  al.  (1999)  1  
Nousiainen  et  al.  (2001) 26  
Schmidt  et  al.  (2002)  4  
Graniewski-Wijnands  and  van  der  Torren  (2002)  9  
Paul  et  al.  (2001)  15  
Lawden  et  al.  (1999)  1  
Observation = progression of VAVFL was determined from either direct 
or from observation of serial quantitative measure of VAVFL, typically pl
graphically in Clayton et al. (2010)).
a when analyzing progression or recovery of visual ﬁelds, the autho
indeterminate, and of >10% as pathologic change.
b Either a paired-samples T-test or a Wilcoxon Signed Rank Test was
ﬁeld size between two predeﬁned test points.
c Also Hardus 2003 (Hardus et al., 2003) reports progression of VAVF
et al., 2000) of 11.263
Studies  of  the  evolution  of  VAVFL  in  people  continuing
GB  therapy  have  followed  participants  for  short  periods
f  time  (Table  1).  In  one  case  report,  which  illustrated  the
volution  of  visual  ﬁeld  size  with  continued  VGB  exposure
ver  a longer  period,  the  visual  ﬁeld  size  showed  a  signif-
cant  decrease  after  ten  years  of  VGB  use,  suggesting  that
AVFL  may  progress  in  some  people  after  many  years  of  VGB
xposure  (Clayton  et  al.,  2010).
Understanding  the  evolution  of  VAVFL  with  continued  VGB
xposure  over  a  long  period  of  time  is  essential  for  optimal
anagement,  enabling  decisions  to  be  made  about  the  risks
nd  beneﬁts  of  continued  therapy.
We  assessed  the  evolution  of  VAVFL  over  a  ten  year  period
n  people  taking  VGB.  We  hypothesised  that  VAVFL  progresses
ith  increasing  cumulative  VGB  exposure.
ethods
he  project  was  approved  by  the  local  institutional  ethics
ommittee.  All  participants  provided  written,  informed  con-
ent.
ubjects  and  recruitment
01  VGB-exposed  individuals  with  epilepsy  were  recruited
rom  specialist  National  Health  Service  clinics  of  the
ational  Hospital  for  Neurology  and  Neurosurgery  as  part
f  a  large  study  of  VAVFL  (Clayton  et  al.,  2011).  From  this
ohort,  all  individuals  who  were  currently  being  treated  with
GB  were  identiﬁed  and  were  recruited  to  take  part  in  this
tudy.  Fourteen  individuals  were  identiﬁed  in  total.  All  14
isual  ﬁeld  with  continued  VGB  exposure.
ollow-up  (months)  Overall  conclusion  How  the  data
were  analysed
20  Progression  Observation
6—67  No  progression  Criteria a
13—61  Progression  Statistical  test b
18—43  No  progression  Observation
Statistical  test b
39  No  progression  Observation
4—38  No  progression  Observation
Statistical  test b
12—24  No  progression  Observation
Statistical  test b
18  No  progression  Observation
12  No  progression  Observation
Statistical  test b
11  Progression  Observation
observation and qualitative evaluation of serial visual ﬁeld data,
otted in a graphical format (e.g. serial MRD measurements shown
rs considered a change in MRD of ≤5% as stable, of 6—10% as
 used to determine a statistically signiﬁcant difference in visual
L in ﬁve people who were included in the earlier report (Hardus
264  L.M.  Clayton  et  al.
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Figure  1  Visual  ﬁeld  size  in  relation  to  cumulative  VGB  exposure  for  each  Subject:  Graphs  for  each  individual  showing  the  visual
ﬁeld size  in  mean  radial  degrees  (MRD)  at  each  successive  examination  (represented  by  ),  in  relation  to  the  cumulative  vigabatrin
(VGB) exposure  at  that  time.  Graphs  are  numbered  according  to  the  subject  number,  and  are  shown  in  order  of  increasing  cumulative
VGB exposure.  A  linear  trendline,  derived  from  all  visual  ﬁeld  results,  was  added  to  each  individual’s  data.  The  slope  of  the  trendline
was determined  using  y  =  mx  +  b,  where  m  =  the  slope  of  the  line.
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had  originally  participated  in  a  study  of  VAVFL  commencing
in  1999  (Newman  et  al.,  2002).  All  were  under  active  neuro-
ophthalmological  follow-up  because  of  VGB  use.  None  had
a  history  of  ocular  disease,  a  family  history  of  glaucoma,  or
a  history  of  surgery  to  the  eye,  orbit  or  brain.  Data  on  VGB
exposure  were  obtained  from  the  medical  notes.
Perimetry
All  subjects  were  examined  on  at  least  one  occasion  by  a
single  researcher  (LMC)  using  Goldmann  kinetic  perimetry.
Monocular  vision  was  examined,  with  the  non-tested  eye
fully  occluded,  using  V4e,  I4e  and  I2e  stimuli.  Appropriate
full  aperture  spectacle  correction  was  used  for  examination
of  the  central  30◦ of  the  visual  ﬁeld.  Fixation  was  monitored
by  direct  visualisation  of  the  ﬁxating  eye.
Other  examinations  of  the  visual  ﬁeld  were  performed  as
part  of  routine  neuro-ophthalmological  assessment  related
to  VGB  exposure,  and  as  part  of  other  studies  of  VAVFL
V
v
ﬁ
tntinued)
Newman  et  al.,  2002).  These  examinations  were  under-
aken  by  skilled  operators  according  to  clinical  protocols.
Visual  ﬁelds  obtained  by  LMC  were  assessed  for  their
eliability  during  the  examination.  Unreliable  ﬁelds  were
etermined  based  on  false  positive  responses,  ﬁxation  losses
nd  highly  variable  responses  to  the  same  stimulus.  Visual
elds  obtained  by  other  examiners  were  reviewed  retro-
pectively  by  LMC.  The  reliability  of  the  visual  ﬁeld  was
etermined  based  on  the  original  operator’s  comments  on
he  visual  ﬁeld  chart.
ata  analysis
isual  ﬁelds  obtained  from  the  right  eye  were  analysed.
nly  data  from  one  eye  were  analysed  as  it  is  accepted  that
AVFL  is  characterised  by  a  symmetrical  contraction  of  the
isual  ﬁeld  (Wild  et  al.,  1999).  Visual  ﬁelds  were  quanti-
ed  using  mean  radial  degrees  (MRD)  which  was  also  used  in
he  original  study  (Newman  et  al.,  2002).  Using  this  method
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he  radial  distance  in  degrees  of  the  I4e  isopter  was  mea-
ured  from  ﬁxation,  at  12  points,  30◦ apart.  The  MRD  was
etermined  by  calculating  the  average  radial  distance  in
egrees  from  the  12  points.  All  assessments  were  quantiﬁed
nd  analysed  by  one  researcher.
The  cumulative  VGB  exposure  at  the  time  of  each  visual
eld  examination  was  determined,  and  a  graph  of  cumula-
ive  VGB  exposure  and  MRD,  at  successive  examinations  over
he  follow-up  period,  was  plotted  for  each  person  (Fig.  1).
 linear  trendline,  derived  from  all  visual  ﬁeld  results,  was
dded  to  each  subject’s  data  (Fig.  1).  The  slope  of  the  trend-
ine  was  determined  using  y  =  mx  +  b,  where  m  =  the  slope  of
he  line.
For  further  analysis,  the  ﬁrst  recorded  visual  ﬁeld  assess-
ent  whilst  on  VGB  (Test  1)  and  the  latest  recorded
ssessment  whilst  still  taking  VGB  (Test  2)  were  considered.
isual  ﬁelds  taken  during  Test  1  and  Test  2  were  classiﬁed  as
ormal  or  showing  mild,  moderate  or  severe  VAVFL  accord-
ng  to  described  criteria  (Wild  et  al.,  1999).  Follow-up  time
as  deﬁned  as  the  time  in  months  between  Test  1  and  Test
.
esults
ubject  data
76  visual  ﬁeld  tests  (median  number  of  examinations  per
ubject  =  13)  from  fourteen  people  (64%  male)  were  avail-
ble.  Two  visual  ﬁeld  tests  were  excluded  (one  each  from
articipant  5  and  7),  as  the  operator  had  indicated  that
he  results  were  unreliable,  leaving  174  visual  ﬁeld  tests
vailable  for  analysis.  One  individual  included  in  this  study
Subject  12)  has  previously  been  reported  (Clayton  et  al.,
010).
Details  of  VGB  exposure,  concomitant  antiepileptic  drug
xposure,  seizure  frequency,  follow-up  time  and  visual  ﬁeld
ize  for  each  participant  are  shown  in  Tables  2  and  3.
nalysis  of  visual  ﬁeld  data  at  Test  1  and  Test  2
isual  ﬁeld  classiﬁcation
t  Test  1,  9/14  (64.3%)  individuals  had  VAVFL.  At  Test  2,
3/14  (92.9%)  individuals  showed  VAVFL.  Six  individuals  had
rogressed  by  at  least  one  class  (e.g.  from  normal  to  mild
AVFL).  Seven  remained  within  the  same  class.  One  individ-
al  (Subject  2)  showed  an  improvement  from  moderate  to
ild  VAVFL,  but  only  when  considering  data  at  Test  1  and
est  2  (Table  2).
isual  ﬁeld  size
 Wilcoxon  Signed  Rank  Test  showed  that  the  visual  ﬁeld
t  Test  2  was  signiﬁcantly  smaller  than  at  Test  1  (z  =  −2.48;
 <  0.05;  Table  2).  The  average  difference  in  visual  ﬁeld  size
etween  Test  1  and  Test  2  was  7.5  MRD.
ndividuals  with  normal  visual  ﬁelds  at  Test  1
ive  people  (Subjects  1,  4,  5,  9  and  10)  had  normal  visual
elds  at  Test  1  (Table  2).  At  Test  2  one  showed  a  normal  visual
eld  according  to  the  classiﬁcation  criteria,  two  showed
ild  VAVFL  and  two  showed  moderate  VAVFL.
ﬁ
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s
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nalysis  of  all  available  visual  ﬁeld  data
volution  of  VAVFL
 graph  of  cumulative  VGB  exposure  and  MRD  at  succes-
ive  examinations  was  plotted  for  each  subject  and  a  linear
rendline  was  added.  The  trendline  showed  a  negative  trend
or  all  subjects,  suggesting  an  overall  decrease  in  the  visual
eld  size  with  increasing  cumulative  VGB  exposure.  Fluctu-
tions  in  visual  ﬁeld  size  were  seen  for  all  subjects  (Fig.  1).
ate  of  change  of  visual  ﬁeld  size
he  rate  of  change  of  the  visual  ﬁeld  size  was  determined
or  each  subject  from  the  slope  of  the  trendline  and  ranged
rom  0.4  to  3.7  MRD  loss  per  kilogram  of  cumulative  VGB
ose  (Table  2).
iscussion
his  is  the  longest  follow-up  study  of  VAVFL  in  people  con-
inuing  VGB  therapy,  and  shows  the  evolution  of  VAVFL  with
ncreasing  VGB  exposure.  The  results  suggest  VAVFL  pro-
resses  with  continued  VGB  use.  The  prevalence  of  VAVFL
ncreased  from  64%  at  Test  1  to  93%  at  Test  2.  All  people
ncluded  in  the  study  showed  a  trend  for  decreasing  visual
eld  size  with  increasing  cumulative  VGB  exposure  when
ll  ﬁelds  for  a  subject  were  taken  into  account  (Fig.  1).
ur  results  concur  with  a  previous  report  of  an  increase
n  the  percentage  visual  ﬁeld  loss  with  continued  VGB  use
ver  a  13—61  month  follow-up  period  in  11  individuals
Hardus  et  al.,  2000).  The  majority  of  studies,  however,  have
eported  that  once  established,  VAVFL  is  stable  and  does
ot  progress  further  with  continued  VGB  use  (Lawden  et  al.,
999;  Nousiainen  et  al.,  2001;  Paul  et  al.,  2001;  Graniewski-
ijnands  and  van  der  Torren,  2002;  Schmidt  et  al.,  2002;
est  and  Acheson,  2005).  The  conﬂicting  evidence  regarding
he  evolution  of  VAVFL  with  continued  VGB  exposure  may  be
ue  to  a  number  of  factors.  Good,  prospective  data  on  the
ourse  of  VAVFL  are  lacking  (Kinirons  et  al.,  2006),  and  most
tudies,  including  our  study,  rely  on  retrospective  analysis
f  visual  ﬁeld  data  acquired  by  different  examiners  over
any  years.  Perimetry  also  has  inherent  limitations  which
ay  make  it  impractical  to  detect  changes  in  the  visual  ﬁeld
ver  time  in  VGB-exposed  individuals,  particularly  if  these
hanges  are  small  and  follow-up  periods  are  short.
roblems  with  measuring  the  visual  ﬁeld
n  many  people  with  epilepsy,  perimetric  results  may  be
nreliable  and  repeated  testing  is  often  needed,  after  which
esults  can  still  prove  difﬁcult  to  interpret  (Wild  et  al.,
006).  In  this  study,  evaluation  of  serial  visual  ﬁeld  tests
howed  a  variable  degree  of  ﬂuctuation  above  and  below  the
rendline  (Fig.  1).  These  ﬂuctuations  are  likely  to  represent
‘normal’’  variability  that  is  not  related  to  VGB-associated
athological  change,  but  are  the  result  of  both  subject-
elated  and  examiner-related  factors  (Parrish  et  al.,  1984).
Subject-related  factors  inﬂuencing  the  recorded  visual
eld  include  fatigue  (Wild  et  al.,  1991),  reaction  time
Becker  et  al.,  2005),  an  inadequate  explanation  or  under-
tanding  of  the  task  (Parrish  et  al.,  1984;  Kutzko  et  al.,
000)  and  a ‘‘learning  effect’’  whereby  individuals  show  an
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Table  2  VGB  exposure  and  visual  ﬁeld  data  for  each  Subject.
Subject  (number  of  visual  ﬁelds) Maximum  daily
VGB  dose  (g)
Cumulative  VGB
exposure  (g)
Duration  of
therapy  (months)
Follow-up
(months)
Test  1 Test  2 Rate  of  change
of MRD/kg  of
VGB  exposureb
Test  1 Test  2 Test  1 Test  2 MRD  Classiﬁcation  MRD  Classiﬁcation
1  (8) 2.5 7606  13,806  122  230  108  52  Normal  38  Mild  −1.3
2 (10) 2.0 6570  14,427  84  213  129  32  Moderate  39  Mild  −0.4
3 (17) 2.0 3134  11,654  45  185  140  34  Moderate  28  Moderate  −1.1
4 (13) 2.0 2086  8640  35  144  109  50  Normal  33  Moderate  −2.2
5 (16)  0.5  1220  3141  58  190  132  50  Normal  51  Normal  −1.8
6 (16)  3.0  4286  8961  43  170  127  38  Mild  37  Mild  −1.4
7 (9)  3.0  7398  20,085  91  230  139  35  Moderate  29  Moderate  −0.9
8 (6) 2.0 221  4432  5  139  134  25  Moderate  28  Moderate  −0.9
9 (4) 2.0 6299  12,627  112  216  104  52  Normal  43  Mild  −0.6
10 (13) 3.0 11,629  16,247  121  235  114  46  Normal  30  Moderate  −3.7
11 (17) 1.5 1367  7154  20  164  144  34  Moderate  26  Moderate  −1.6
12 (21) 3.0 6297  18,950  49  197  148  32  Moderate  1  Severe  −2.7
13 (10) 2.0 2516  10,250  36  162  126  41  Mild  38  Mild  −2.4
14 (14) 2.0 5632  13,106  83  216  133  36  Mild  31  Moderate  −1.1
Average (SD) 2.0  (0.5—3.0)a 4737  11,677  64.6  192  (32.4)127.6  (14.0)  39.8  (8.8)  32.3  (11.3)
VGB = vigabatrin; MRD = mean radial degrees; Test 1 = ﬁrst visual ﬁeld examination taken whilst on VGB; Test 2 = latest visual ﬁeld examination taken whilst on VGB.
a Median (range).
b Determined from the slope of the trendline using y = mx + b, where m = the slope of the line. Note if only results at Test 1 and Test 2 are considered, some individuals would have been
thought not to show any progression.
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Table  3  Clinical  data  for  each  Subject.
Subject  Age  at  Test
2  (years)
All  other  AEDs  exposed  to
during  VGB  exposure
AEDs  exposed  to  at  Test  1  and  Test  2  (dose  of  VGB  in  grams)  Seizure  frequency  at  Test  1  and  Test  2a
Test  1  Test  2  Test  1  Test  2
1  52  CBZ  VGB  (2.0),  CBZ  VGB  (1.5)  Seizure  free  Seizure  free
2 39  CBZ,  CLN,  PHT  VGB  (2.0),  CBZ,  CLN  VGB  (2.0),  CBZ,  CLN,  PHT  Frequent  nocturnal
complex  partial  seizures
Frequent  nocturnal  complex
partial  seizures
3 44  VPA,  CBZ,  OXC  VGB  (2.0),  VPA,  CBZ  VGB  (2.0),  VPA,  OXC,  CBZ  Daily  myoclonic  jerks.  One
GTCS  per  week
Daily  myoclonic  jerks.  Three
to four  GTCS  per  month
4 38  VPA  VGB  (2.0),  VPA  VGB  (2.0),  VPA  Seizure  free  Seizure  free
5 40  CBZ  VGB  (0.5),  CBZ  VGB  (0.5),  CBZ  Seizure  free  Seizure  free
6 33  CBZ,  TPM,  TGB,  PHB,  PGB,
ZON,  LAC
VGB  (3.0),  CBZ,  TPM,  TGB  VGB  (1.0),  CBZ  TPM,  LAC  30-38  seizures  per  month  Five  to  six  seizures  per  day
7 46  CBZ,  PMD,  LEV,  TPM  VGB  (3.0),  CBZ,  PMD  VGB  (1.5),  CBZ,  LEV,  TPM  No  detailsb Six  ‘‘mild  seizures’’  per
month
8 51  CBZ,  TPM,  PHB,  CLB,  LEV,  VGB  (2.0),  CBZ,  TPM,  PHB,
CLB
VGB  (2.0),  CBZ,  LEV,  CLB  Four  to  ﬁve  complex
partial  seizures  per  day
Daily  complex  partial
seizures
9 53  GBP  VGB(2.0),  GBP  VGB  (2.0),  GBP  Data  unavailablec Clusters  of  complex  partial
seizures  every  few  months
10 56  CBZ,  CLB,  LEV  VGB  (3.0),  CBZ,  CLB  VGB  (0.5),  CBZ,  CLB,  LEV  Seizures  every  two  months  ‘‘Unsure’’  (monthly
seizures  recorded  six
months  before  T2)
11 49  CBZ  VGB  (1.5),  CBZ  VGB  (1.5),  CBZ  Seizure  free  Seizure  free
12 36  CBZ,  GBP,  TPM,  LAC  VGB  (3.0),  CBZ,  GBP  VGB  (3.0),  CBZ,  TPM,  LAC  Three  complex  partial
seizures  per  week
Several  complex  partial
seizures  per  week
13 36  LEV,  CLB,  data  missingd VGB  (2.0),  data  missingd VGB  (2.0),  LEV,  CLB  Data  unavailablec Seven  seizures  in  six  months
14 63  CBZ,  LEV  VGB  (2.0),  CBZ  VGB  (2.0),  CBZ  Weekly  simple  partial
seizures
Seizure  free
AED, antiepileptic drug; CBZ, carbamazepine; CLB, clobazam; CLN, clonazepam; GBP, gabapentin; LAC, lacosamide; LEV, levetiracetam; OXC, oxcarbazepine; PHB, phenobarbital; PHT,
phenytoin; PGB, pregabalin; PMD, primidone; TGB, tiagabine; TPM, topiramate; VPA, valproate. Data are taken from case notes. Recording standards have changed over the time course
of VGB exposure, such that some data are unavailable.
a Seizure frequency taken from the clinic letter closest to the time that the visual ﬁeld assessment was performed.
b Details of seizure frequency not provided in clinic letters from that time period.
c Clinic letters regarding seizure frequency unavailable from this time period.
d Full details of concomitant AED use during early VGB exposure period unavailable.
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sEvolution  of  visual  ﬁeld  loss  on  vigabatrin  
improvement  of  the  visual  ﬁeld  over  subsequent  test  ses-
sions  related  to  improved  performance  and  familiarity  with
the  task  (Heijl  et  al.,  1989;  Wild  et  al.,  1989).  In  healthy  peo-
ple,  the  visual  ﬁeld  size  was  found  to  ﬂuctuate  by  up  to  16%
between  test  sessions  (Ross  et  al.,  1984).  In  individuals  with
visual  impairment  due  to  retinitis  pigmentosa,  the  ﬂuctua-
tion  in  visual  ﬁeld  size  not  related  to  disease  progression  was
as  high  as  50%  between  sessions  in  some  (Ross  et  al.,  1984).  In
people  with  epilepsy,  ﬂuctuations  in  visual  ﬁeld  size  may  be
exaggerated.  Certain  antiepileptic  drugs  (Aldenkamp,  2001;
Hessen  et  al.,  2006),  seizures,  the  underlying  cause  of  the
epilepsy  and  psychosocial  factors  (Meador,  2002)  can  impair
cognition,  attention  and  psychomotor  speed,  all  of  which
are  integral  to  performing  perimetry  reliably.  As  these  fac-
tors  may  ﬂuctuate  over  time,  their  inﬂuence  on  the  recorded
visual  ﬁeld  may  also  ﬂuctuate,  exaggerating  the  normal
variability  between  test  sessions,  and  making  it  difﬁcult  to
detect  true  pathological  change  (Parrish  et  al.,  1984).
Examiner-related  factors  may  also  contribute  to  the  vari-
ability  in  the  recorded  visual  ﬁeld  (Berry  et  al.,  1966;
Nowomiejska  et  al.,  2005;  Ramirez  et  al.,  2008),  particu-
larly  when  using  a  manual  perimetric  technique  (Kolling  and
Wabbels,  2000).  The  speed  and  direction  of  movement  of
the  light-stimulus  which  is  used  to  assess  the  visual  ﬁeld
is  operator-dependent.  Optimal  rates  of  stimulus  move-
ment  have  been  suggested  (Greve  et  al.,  1976;  Johnson  and
Keltner,  1987),  but  the  speed  and  technique  used  by  an  oper-
ator  may  be  inﬂuenced  by  the  subject’s  performance  and
ability,  the  time  constraints  of  the  clinical  setting  and  the
examiner’s  skill  and  experience  (Johnson  and  Keltner,  1987;
Nowomiejska  et  al.,  2005).  The  instructions  given  by  the
examiner  on  how  to  perform  the  assessment  can  also  affect
the  obtained  visual  ﬁeld  result  (Kutzko  et  al.,  2000).
Problems  with  detecting  and  deﬁning  progression
of VAVFL
Several  studies  of  VAVFL  have  attempted  to  overcome  the
effects  of  ‘‘normal’’  ﬂuctuation  on  detecting  progression
of  VAVFL  by  using  criteria  to  deﬁne  pathological  change  in
visual  ﬁeld,  including  a  change  in  the  visual  ﬁeld  of  ≥10%
(Kinirons  et  al.,  2006)  or  of  more  than  10  MRD  (Newman
et  al.,  2002;  Best  and  Acheson,  2005).  The  disadvantage  of
using  these  arbitrary  criteria  is  that  they  may  miss  small
pathological  changes  (Kinirons  et  al.,  2006).  For  example,
whilst  all  participants  in  this  study  show  a  trend  for  pro-
gression  of  VAVFL  when  all  visual  ﬁeld  tests  were  considered
(Fig.  1),  only  four  (Subjects  1,  4,  10  and  12)  show  a  decrease
in  visual  ﬁeld  size  of  ≥10  MRD  when  comparing  Test  1  and
Test  2  (Table  2).
The  small  degree  of  change  in  the  visual  ﬁeld  size  with
increasing  VGB  exposure  may  be  difﬁcult  to  detect  clini-
cally  if  serial  results  are  assessed  subjectively  for  evidence
of  progression  (Parrish  et  al.,  1984),  a  method  that  has  been
utilised  in  some  studies,  or  when  follow-up  periods  are  short
(Table  1).  Failure  to  detect  progression  of  VAVFL  may  also
relate  to  the  analysis  used  in  some  studies.  In  this  study,
Subject  2  showed  an  apparent  improvement  in  the  visual
ﬁeld  from  moderate  VAVFL  at  Test  1  to  mild  VAVFL  at  Test
2  when  considering  only  these  two  time  points  (Table  2).
When  all  time  points  were  considered,  however,  the
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rendline  indicated  a  progressive  decrease  in  visual  ﬁeld  size
ver  the  follow-up  period  (Fig.  1).  Many  studies  of  VAVFL
rogression  have  used  analysis  techniques  where  only  two
isual  ﬁeld  test  points  were  taken  into  account  to  deter-
ine  whether  a  change  has  occurred  (Table  1).  If  any  of  the
est  points  used  in  an  analysis  were  signiﬁcantly  inﬂuenced
y  non-pathological  variation,  then  the  analysis  may  fail  to
etect  a  change  in  the  visual  ﬁeld  size.  The  present  study
s  also  subject  to  all  of  the  subject-  and  examiner-related
actors  discussed;  however,  the  advantage  is  that  for  each
ndividual  all  available  reliable  results  were  used  in  the  eval-
ation  of  progression  (Fig.  1).  Quantifying  and  graphically
llustrating  the  visual  ﬁeld  results  from  all  available  exami-
ations  enables  detection  of  trends  in  changing  visual  ﬁeld
ize  (either  qualitatively  or  by  applying  a  trendline  to  the
ata),  whilst  allowing  for  the  effect  of  ‘‘normal’’  variability.
It  is  important  to  note  that  the  rate  of  progression  of
AVFL  appears  to  differ  between  individuals.  For  example,
n  our  study,  Subject  2  and  Subject  12  were  followed  up
ver  similar  VGB  exposure  durations  and  had  similar  visual
elds  at  Test  1.  In  the  follow-up  period,  the  average  rate
f  loss  for  Subject  12  was  higher  (2.7  MRD/kg  cumulative
GB  exposure),  leading  to  severe  VAVFL,  whilst  Subject  2
howed  a  more  slowly  progressive  course  (0.4  MRD/kg  cumu-
ative  VGB  exposure),  with  the  visual  ﬁeld  size  showing  little
hange  over  time  (Table  2;  Fig.  1).  The  inter-individual  dif-
erences  in  the  rate  of  progression  of  VAVFL  may  account
or  some  of  the  variation  in  susceptibility  to  VAVFL  seen  in
ndividuals  exposed  to  similar  amounts  of  VGB.  This  ﬁnd-
ng  may  have  implications  for  phenotyping  in  drug  response
tudies  of  VAVFL.  Current  understanding  of  the  relation-
hip  between  VGB  exposure  and  visual  ﬁeld  loss  comes  from
ross-sectional  studies  typically  looking  at  visual  ﬁeld  size
fter  a  given  VGB  exposure.  The  rate  of  change  in  the  visual
eld  size  with  increasing  cumulative  VGB  exposure  may,
owever,  provide  a  stronger  indicator  of  a  person’s  risk  of
eveloping  signiﬁcant  VAVFL,  and  may  provide  a  more  useful
easure  to  consider  in  the  management  of  people  continu-
ng  VGB  therapy.
At the  time  of  Test  1,  the  average  duration  of  VGB  expo-
ure  was  ﬁve  years,  and  9/14  individuals  had  VAVFL.  We  note
hat  the  true  pattern  of  visual  ﬁeld  loss  may  not  be  lin-
ar,  and  that  the  progression  observed  in  the  present  study
ay  not  represent  the  pattern  and  rate  of  progression  of
AVFL  prior  to,  or  subsequent  to,  the  observation  period.
e  have  simply  used  one  method  (trendline  interpolation)
o  illustrate  progression.  Prospective  longitudinal  studies
ncluding  visual  ﬁeld  examinations  prior  to  VGB  exposure  are
eeded  to  fully  elucidate  the  pattern  of  VAVFL  onset  and
rogression.  In  addition,  including  analysis  of  visual  ﬁelds
n  a  control  group  of  individuals  with  epilepsy  who  have  no
xposure  to  VGB,  but  are  matched  in  terms  of  sex,  age,
eizure  frequency  and  concomitant  antiepileptic  drug  use,
ay  overcome  subject-related  ﬂuctuations  in  visual  ﬁeld
ize.
In  this  study  we  have  not  considered  the  effect  of  increas-
ng  age  on  visual  ﬁeld  size  over  the  follow-up  period.  Visual
ensitivity  declines  with  increasing  age  (Spry  and  Johnson,
001).  In  the  ﬁrst  six  decades  of  life  this  effect  is  small  (Spry
nd  Johnson,  2001).  13/14  people  included  in  this  study
ere  less  than  60  years  old  at  the  time  of  Test  2  (Table  2),
hus  any  contribution  of  increasing  age  to  the  change  in
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isual  ﬁeld  size  over  the  follow-up  period  is  likely  to  have
een  small.
ew  methods  are  needed
erimetry  may  not  be  the  most  appropriate  tool  for  monitor-
ng  visual  dysfunction  in  VGB-exposed  people.  New  methods
o  assess  the  effects  of  VGB  retinotoxicity  are  needed,
articularly  in  those  in  whom  perimetry  is  unreliable  or
nfeasible.  Electroretinography  has  been  explored  as  a
otential  tool  to  monitor  VGB  retinotoxicity;  however,  no
easure  has  consistently  shown  to  be  associated  with  the
resence  or  severity  of  VAVFL  (Wild  et  al.,  2006).
Peripapillary  retinal  nerve  ﬁbre  layer  thinning  measured
sing  optical  coherence  tomography  has  been  suggested  to
e  a  sensitive  and  speciﬁc  indicator  of  VAVFL  (Lawthom
t  al.,  2009;  Clayton  et  al.,  2011)  and  provides  an  objec-
ive  tool,  with  highly  repeatable  measures  in  VGB-exposed
ndividuals  (Clayton  et  al.,  2011).  Owing  to  the  limited  avail-
bility  of  commercial  optical  coherence  tomography,  and
he  relatively  recent  suggestion  for  its  use  in  the  assess-
ent  of  VGB-exposed  people  (Lawthom  et  al.,  2009;  Clayton
t  al.,  2011),  longitudinal  data  on  changes  in  the  peripapil-
ary  retinal  nerve  ﬁbre  layer  with  continued  VGB  exposure
re  not  currently  available.  Further  studies  are  needed  to
dentify  whether  measures  of  peripapillary  retinal  nerve
bre  layer  thickness  provide  a  suitable  tool  for  the  assess-
ent  of  progression  of  VGB  retinotoxicity  and  associated
isual  dysfunction.
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